OVERVIEW

Treating Central Catheter-Associated Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Beyond Vancomycin is organized by American Association of Critical-Care Nurses (AACN) and will be held from Aug 01, 2016 - Aug 01, 2020.

Credits:
Contact Hours 1.00
CERP A 1.00
Pharmacology Hours 0.50

Activity Summary:
Methicillin-resistant Staphylococcus aureus is a frequent cause of hospital-associated infections, including central catheter–associated bacteremia. Vancomycin has been the drug of choice for treating this type of bacteremia for decades in patients who have no contraindications to the antibiotic. However, resistance to vancomycin is an emerging problem. Newer antibiotics approved by the Food and Drug Administration have activity against methicillin-resistant S aureus. Some of the antibiotics also have activity against strains of S aureus that are intermediately susceptible or resistant to vancomycin. This article uses a case study to highlight the clinical signs of vancomycin failure and describes the indications for and appropriate use of alternative antimicrobials such as ceftaroline, daptomycin, linezolid, tigecycline, and telavancin.

Objectives:
• Discuss the signs of vancomycin failure in the treatment of MRSA central-line-associated bacteremia.
• Describe the indications for use of daptomycin and ceftaroline for treatment of MRSA central line-associated bacteremia.
• Verbalize at least two nursing interventions which help prevent MRSA central line-associated bacteremia.

Additional details will be posted as soon as they are available.